OneSource and BRL ink technology licensing agreement to deliver high-concentration biologics subcutaneously
Revolutionary technology will further boost OneSource’s scientific services offerings
Revolutionary technology will further boost OneSource’s scientific services offerings
The approved product has an estimated market size of US$ 268 million for the twelve months ending June 2024, according to IQVIA
Finerenone significantly reduced the composite of cardiovascular death and total (first and recurrent) heart failure events compared to placebo in addition to usual therapy
Shivani Satish Wagh takes on the role of Joint Managing Director
EBITDA at Rs. 250 crore, up 47% YoY, with 35% EBITDA margin
Nelarabine is a nucleoside metabolic inhibitor indicated for the treatment of patients with T-cell acute lymphoblastic leukemia
Sun Pharmaceutical Industries has reported total income of Rs. 13,185.30 crores during the period ended June 30, 2024
The New Drug Application (NDA) includes data from the Phase III studies OASIS 1, 2 and 3 - showing elinzanetant significantly reduced the frequency and severity of moderate to severe vasomotor symptoms over 12 weeks compared to placebo
The acquisition will further strengthen Barentz’ position in India creating a leading life science distribution platform
Subscribe To Our Newsletter & Stay Updated